Robert Renouard, MD
Urology · Oklahoma City, OKNPI 1265492144
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,183 of the $9,043 with a category attached, or 68.4%. 35 manufacturers reported payments, led by Teleflex LLC at 29.4% of the total. Reporting peaked in 2022 at $3,884 and has fallen 84.9% since, to $585 in 2025.
Across 189 payments — averaging $47.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$3K
- Palette Life Sciences, Inc.$1K
- Urogen Pharma, Inc.$950
- Profound Medical Corp.$843
- Astellas Pharma US Inc$612
- Medtronic$340
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2,60829%
- Food & beverage$6,18368%
- Education$2533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 27 | $2,661 |
| Palette Life Sciences, Inc. | 5 | $1,329 |
| Urogen Pharma, Inc. | 25 | $950 |
| Profound Medical Corp. | 2 | $843 |
| Astellas Pharma US Inc | 33 | $612 |
| Medtronic | 6 | $340 |
| Healthtronics Stone Solutions, LLC | 3 | $268 |
| Sumitomo Pharma America, Inc. | 12 | $261 |
| Coloplast | 5 | $261 |
| Boston Scientific | 6 | $209 |
| AbbVie(2 entities) | 4 | $192 |
| Pfizer | 9 | $164 |
| Urovant Sciences Inc | 10 | $144 |
| Accord Healthcare, Inc. | 5 | $91 |
| Blue Earth Diagnostics | 5 | $91 |
| Tolmar Pharmaceuticals, Inc. | 5 | $88 |
| Myovant Sciences Inc. | 3 | $59 |
| EDAP Technomed Inc | 1 | $53 |
| Convatec Inc. | 2 | $49 |
| Neotract Inc. | 2 | $40 |
| Tolmar, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 2 | $36 |
| Amgen | 2 | $27 |
| Olympus America Inc. | 1 | $25 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Immunitybio, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Innocoll Pharmaceuticals Limited | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Civco Medical Instruments | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$1,121
- Tulsa-Pro$843
- UroLift$606
- JELMYTO$520
- Barrigel$264
- INTERSTIM$253
- Mobile Cryoblation Services$205
- TITAN$150
- BOTOX$137
- GENERAL BPH$125
How this compares
$9,043 in reported general payments places this provider in the 75th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 146 | $146,746 |
| GemtesaVibegron | 30 | $19,245 |
| Finasteride | 917 | $15,090 |
| Methenamine Hippurate | 167 | $14,283 |
| Tamsulosin Hcl | 652 | $10,516 |
| Potassium Citrate ErPotassium Citrate | 112 | $8,027 |
| Dutasteride | 163 | $6,272 |
| PremarinEstrogens, Conjugated | 16 | $4,037 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 105 | $3,106 |
| Bethanechol Chloride | 40 | $2,239 |
| Oxybutynin Chloride | 85 | $1,903 |
| Estradiol | 35 | $1,839 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 81 | $1,767 |
| Lubiprostone | 17 | $1,261 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 85 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $612 | $146,746146 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $261 | $19,24530 claims |
| PfizerPremarin | $164 | $4,03716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 urology providers in Oklahoma.
Other urology in Oklahoma City
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Basel HassounOklahoma City$20K
- Johnny HicksonOklahoma City$16K
- Michael HolzerOklahoma City$15K
- Dominic FrimbergerOklahoma City$12K
- Aaron BenhamOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.